Home/Pipeline/SP-537

SP-537

Pancreatic Cancer

PreclinicalActive

Key Facts

Indication

Pancreatic Cancer

Phase

Preclinical

Status

Active

Company

Stamford Pharmaceuticals

About Stamford Pharmaceuticals

Stamford Pharmaceuticals is a private, clinical-stage biotech advancing an oncolytic adenovirus platform, SP-002, primarily for skin cancers like Basal Cell Carcinoma (BCC). The company has reported positive Phase 2 results and is planning a Phase 3 trial for 2025/26, while also exploring its vector-drug conjugate platform for pancreatic and bladder cancers. Led by a small, experienced team with industry and investment backgrounds, Stamford is positioned in the growing cell and gene therapy sector but faces significant development and competitive risks common to early-stage oncology biotechs.

View full company profile

Therapeutic Areas

Oncology Dermatological Oncology

Other Pancreatic Cancer Drugs

Drug	Company	Phase	Status
Ampligen® (rintatolimod)	AIM ImmunoTech	Early Access Program	Active - Approved in the Netherlands at Erasmus MC
HBM9027	Harbour BioMed	Phase 1	Active (Global)
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
AHPBA IRE Registry	AngioDynamics	Post-Market Registry	Active
SIMBs + Immunotherapy	Advanced Microbubbles	Pre-clinical	Validated in preclinical studies
CLS-014	CLS Therapeutics	Pre-clinical	Lead candidate
SOMA Platform	Coherence Neuro	Pre-clinical	Pipeline expansion launched in 2024
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Orphan Drug Designated (Jan 2026)
Pritumumab (PTB)	Nascent Biotech	Phase II (Planned)	Exploratory
Pancreatic Cancer Test	Mosaique Diagnostic	Development	Active
Iontophoretic System	Continuity Biosciences	Pre-clinical	Active
Lixumistat (IM156)	ImmunoMet Therapeutics	Phase 1b	Active